About JETREA®

JETREA® in the US

ThromboGenics’ lead product, JETREA®, has been approved by the US Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (sVMA) and was launched in January 2013. Please consult clinicaltrials.gov for an overview of ongoing clinical studies.

For more information on the use and availability of JETREA® in the US, or if you would like to contact our customer service department, please consult the dedicated website www.jetrea.com (for US residents only).

 

JETREA® elsewhere in the world

In Europe, JETREA® has been approved by the European Commission for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Together with our commercial partner Alcon, ThromboGenics is making excellent progress on bringing JETREA® closer to the market in many regions in the rest of the world. We have reached major market access milestones in Asia, Latin America, Australia, the Ukraine and Japan.

For more information on the use and availability of JETREA® outside the US, please consult the website of our commercial partner Alcon: www.alcon.com.

 

JETREA® - Registration Status

 
1 - Registration planned/under evaluation
 
2 - Reimbursement planned/under evaluation
 
3 - Approved & reimbursed